Company
Headquarters: Boulder, CO, United States
Employees: 45
CEO: Dr. Jonathan Violin M.B.A., Ph.D.
$2.93 Billion
USD as of Jan. 1, 2026
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody for the treatment of thyroid eye disease; VRDN-002, a biosuperior IGF-1R antibody; and VRDN-003, an IGF-1R antibody product specifically designed for thyroid eye disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.
| Last Financial Reports Date | Sept. 30, 2025 |
| Revenue TTM | $70.8 M |
| EBITDA | $-324,155,008 |
| Gross Profit TTM | $-247,392,000 |
| Profit Margin | 0.00% |
| Operating Margin | -56.70% |
| Quarterly Revenue Growth | 81958.10% |
Viridian Therapeutics, Inc. has the following listings and related stock indices.
Stock: NASDAQ: VRDN
Stock: FSX: 1S1